Examples for such markers/targets, in the case of breast cancer, are the oestrogen receptor (ER), progesterone receptor (PgR), and the Erb2/Her2 molecule, a receptor tyrosine protein kinase that is overexpressed in a subset of breast cancers. There are number of treatment options for tumours that express the ER, PgR or Her2 receptors, however up to 20 percent of the newly diagnosed cases belong to a subset, which is negative for all three of the receptor molecules. This presentation will discuss applications of high-resolution hybrid mass spectrometry for quantitative genome-scale studies of protein abundance and post-translational modifications. The current state-of-the-art technology for large-scale proteome analysis of individual solid tumours is discussed. Case studies from experiments with triple-negative breast and colorectal tumours illustrating the capability of the proteome-based strategies are presented, as well as mechanistic investigations in cultured cells that have been informed by tumour proteomics and focus on specific phosphorylation hotspots and protein interactions of the tumour suppressor Scribble.
Genome-Scale Protein Expression Analysis of Individual Solid Tumors
Video May 12, 2015
Researchers at MIT have developed half-inch modular blocks that can be constructed to produced different diagnostic devices. They hope that their low-cost, easy-to-assemble half-inch creations will soon land in the hands of many small laboratories around the world, to improve infection detection and monitoring.WATCH NOW
Professor Sir Doug Turnbull from the Wellcome Trust Centre for Mitochondrial Research at the University of Newcastle explains his research into mitochondrial donation, the innovative treatment that hopes to stop faulty mitochondria being passed on from mother to child to prevent incurable genetic diseases.
The first babies conceived with this treatment through IVF may be born in the UK soon.